Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I do not think Noelle is on maternity leave
Unless you can take this leave without being noticeably pregnant..
Checked her FB page and saw pics from Hawaii in March where she is clearly not pregnant or at least not showing..And, if she in fact IS on maternity leave, then someone else would be covering for her.
From your lips to God's ear
maybe Noelle got promoted
to CEO
Meanwhile, back at the ranch..
ADRO +10%
LMAO TC, you da man! (I bet you are really fun at parties)
you know, the 'pull my finger" jokes and such..
So....The big question
When will we have an update on the clinical hold??
Since Mgmt is in "blackout", will this be announced?
BLCM had their hold lifted April 11, nice pop since then..
NSM Non synonymous mutations
Tomorrow is Fri the 13th.
Real witching Friday. oooooh Scary!
This board is even scarier..back and forth, up and down
yes and no..wait...Maybe!
Sell the Beach!
WHO BOUGHT THE 10M SHARES???????
Following the close of our first fiscal quarter, we raised gross proceeds of $20 million in a public offering of 10 million shares of common stock at $2 per share. We were pleased to have the transaction oversubscribed by well-known and respected biotech investors. This relatively modest capital raise was undertaken at this time to strengthen our cash position and allow us to reach a number of near-term inflection points.
When the company refuses to give us answers, we make our own news!
TC, you are kinda crazy :)..But thanks!
Merck got good news this am:
Shares of Merck & Co. Inc. MRK, +3.34% surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytruda as monotherapy for the first-line treatment of metastatic non-small cell lung cancer. The primary endpoint was overall survival. An independent data monitoring committee (DMC) determined that treatment with Keytruda resulted in significantly longer overall survival than platinum-based chemotherapy in tested patients. Based on the DMC's finding, the trial will continue to evaluation progression-free survival, which is the secondary endpoint.
Credit to TC for digging this up...
On February 16, 2017, Takeda completed its acquisition of ARIAD through the merger of Kiku Merger Co., Inc. with ARIAD without a vote of ARIAD’s shareholders pursuant to Section 251(h) if the Delaware General Corporation Law. As a result of the merger, ARIAD became an indirect wholly owned subsidiary of Takeda. In connection with the merger, all ARIAD shares not purchased in the tender offer have been converted into the right to receive $24.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. ARIAD common stock will cease to be traded on the NASDAQ Global Select Market.
https://www.takeda.com/newsroom/newsreleases/2017/Takeda-Completes-Acquisition-of-ARIAD-Pharmaceuticals-Inc/
Ariad utilized this rule with Takeda
Section 251(h), which went into effect for merger agreements signed on or after August 1, 2013, provides that, unless its certificate of incorporation provides otherwise, a publicly-traded Delaware corporation is not required to obtain a stockholder vote to effect a merger if a buyer acquires in a tender offer the percentage of shares that would have been necessary to adopt the merger agreement (typically 50.1%).
https://www.lexisnexis.com/ca/guidance/mergersandacquisitions/document/415544/5F2X-5P01-F003-H2SR-00000-00/Section_251_h__of_the_Delaware_General_Corporation_Law___Overview
See my msg 62391..The recent FB additions another "signal"
ImHo
Michael Grace VP Technical Operations
Thanks TC!, and a friendly reminder that since we are a Delaware Corporation, they do not need shareholder vote for a merger/ acquisition, so we will remain mushrooms I am sure (if in fact that is what is happening)
Agreed, I am in the same camp..Good to have the objectivity also to keep perspective..been fooled many times before..
TC, I give Dew extra credence, he was one of the main reasons I stayed in ARIA long enough to completely capitalize on the best score in my lifetime x10..He is very level headed...sees everything as black or white....Very objective and engineer type if you didnt already know..
That sounds as plausible as the others so maybe there was a setback that caused the delay (EU filing?) But how does the company continue to function properly w/o the 5 execs?
Lmao..
Or maybe they are still on Easter break as some have supposed?
Everybody? Lol I feel like I am in the twilight zone!
Why does stock investing/trading have to be such a big headache?
If it was easy, everyone would be rich..
No pain, No gain (or loss).. and with small bio's
multiply that by 10
No shareholder vote required under Delaware jurisdiction
Mushrooms until the very end! But the mushrooms turned to truffles..
On February 16, 2017, Takeda completed its acquisition of ARIAD through the merger of Kiku Merger Co., Inc. with ARIAD without a vote of ARIAD’s shareholders pursuant to Section 251(h) if the Delaware General Corporation Law. As a result of the merger, ARIAD became an indirect wholly owned subsidiary of Takeda. In connection with the merger, all ARIAD shares not purchased in the tender offer have been converted into the right to receive $24.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. ARIAD common stock will cease to be traded on the NASDAQ Global Select Market.
TC, Thank you for sharing
1.77 now..if this keeps up I'm having steak tonight
Hopefully its Orange and not Grape ;)
I was saving my powder for 1.25 ..my last 5k share buy...I may reconsider that
Gold 007 wrote it, I am replying to it here
TC, see post #61075
Cryptic signals
It is possible that the removal of the 5 execs was done on purpose to send a signal to retail (since we are almost always in the dark)knowing that many would call about this and get no response..also the recent member additions to the facebook page..
(sometimes if you are not allowed to say something with words, you can get your message across with minor actions)
Then again, maybe I am grasping at straws...
As far as ARIA, It allowed me to retire before 50, but there was a ton of pain getting there..swing traded it to get my avg to 1.00 with 100k shares..hoping for similar here albeit I have much fewer shares (initially I bought ARIA 1k at 6.00,and said my all in amt was 5k)..LOL
the trading around 2007 made me feel as though there was no hope at all...
That was just wrong...
the number that is... I heard it was 50! lmao
Sell the Beech!
Why wouldn't management PR this new patent?
Is it not relevant enough? I have seen plenty of companies issue PR's for new patents..
Not specific to Advaxis, but an interesting read nonetheless
https://www.forbes.com/sites/arleneweintraub/2017/12/26/5-immuno-oncology-developments-to-watch-in-2018/#30f251644b22